e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Complex respiratory infections in clinical practice
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efferent therapy in complex treatment of community-acquired pneumonia in patients with immunosuppression
O. Viltsaniuk (Vinnytsya, Ukraine), Y. Mostovoy (Vinnytsya, Ukraine)
Source:
International Congress 2019 – Complex respiratory infections in clinical practice
Session:
Complex respiratory infections in clinical practice
Session type:
Thematic Poster
Number:
4589
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Viltsaniuk (Vinnytsya, Ukraine), Y. Mostovoy (Vinnytsya, Ukraine). Efferent therapy in complex treatment of community-acquired pneumonia in patients with immunosuppression. 4589
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Hospital-acquired pneumonia in patients receiving immunosuppressive therapy
Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections
Year: 2009
Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia
Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Year: 2012
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010
Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 408s
Year: 2007
Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients
Source: Eur Respir J 2015; 45: 463-472
Year: 2015
The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006
Ertapenem therapy for community-acquired pneumonia in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005
Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009
Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006
Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia.
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019
Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients
Source: Annual Congress 2011 - COPD management
Year: 2011
Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet?
Source: Eur Respir J 2013; 41: 5-6
Year: 2013
Telithromycin is effective in the treatment of high-risk patients with community-acquired pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 561s
Year: 2002
Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP
Source: Eur Respir J 2013; 41: 123-130
Year: 2013
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
How often can we use short course therapy in patients with hospital-acquired pneumonia?
Source: Eur Respir J 2007; 30: Suppl. 51, 408s
Year: 2007
Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007
Combination versus monotherapy for nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 50-55
Year: 2007
Systemic corticosteroid for treating severe community-acquired pneumonia
Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation
Year: 2015
The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept